Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation

Histone deacetylase inhibitors (HDACIs) represent an intriguing class of pharmacologically active compounds. Currently, some HDACIs are FDA approved for cancer therapy and many others are in clinical trials, showing important clinical activities at well tolerated doses. HDACIs also interfere with th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oxid Med Cell Longev
Päätekijät: Borriello, Adriana, Naviglio, Silvio, Bencivenga, Debora, Caldarelli, Ilaria, Tramontano, Annunziata, Speranza, Maria Carmela, Stampone, Emanuela, Sapio, Luigi, Negri, Aide, Oliva, Adriana, Sinisi, Antonio Agostino, Spina, Annamaria, Della Ragione, Fulvio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Hindawi Publishing Corporation 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4670678/
https://ncbi.nlm.nih.gov/pubmed/26682002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2481865
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia